The Library
The relationship between oxygen therapy, drug therapy, and COVID-19 mortality
Tools
Yang, Ling, Chen, Guoxi, Cai, Yuyang, An, Ye, Li, Xiaopan, Chen, Ying, Xu, Cheng, Ji, Chen, Lan, Xing, Wang, Yaling, Huang, Hai and Han, Li (2022) The relationship between oxygen therapy, drug therapy, and COVID-19 mortality. Open Medicine, 17 (1). pp. 1833-1839. doi:10.1515/med-2022-0569 ISSN 2391-5463.
|
PDF
WRAP-relationship-between-oxygen-therapy-drug-therapy-COVID-19-mortality-Chen-2022.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (526Kb) | Preview |
Official URL: http://dx.doi.org/10.1515/med-2022-0569
Abstract
Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19). We conducted a retrospective study of COVID-19 inpatients in Wuhan Pulmonary Hospital (Wuhan, China) from January 1 to February 29, 2020. The subjects were divided into four groups due to different treatment regimes. We used the Kaplan–Meier method to determine the cumulative rates of in-hospital death and the Cox proportional hazard model to calculate the risk factors and corresponding hazard ratios. A total of 185 patients were included in this study. The median age of the patients was 62 years, including 94 men and 91 women. Kaplan–Meier analysis demonstrated that mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. Body mass index (BMI) had no influence on mortality, as well as high flow oxygen therapy, Lopinavir–ritonavir (LPV/r) therapy, and the interferon-alpha add LPV/r therapy. Cox proportional hazard regression confirmed that the low flow oxygen therapy was independent protective factor for in-hospital death after adjusting for age, gender, and BMI. In conclusion, the mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. BMI had no influence on mortality, as well as high flow oxygen therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
Journal or Publication Title: | Open Medicine | ||||||
Publisher: | De Gruyter | ||||||
ISSN: | 2391-5463 | ||||||
Official Date: | 22 November 2022 | ||||||
Dates: |
|
||||||
Volume: | 17 | ||||||
Number: | 1 | ||||||
Page Range: | pp. 1833-1839 | ||||||
DOI: | 10.1515/med-2022-0569 | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||
Date of first compliant deposit: | 21 December 2022 | ||||||
Date of first compliant Open Access: | 21 December 2022 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year